New Zealand markets close in 10 minutes
  • NZX 50

    -15.28 (-0.13%)

    +0.0013 (+0.21%)

    +0.0011 (+0.18%)

    +6.10 (+0.08%)
  • ASX 200

    +10.50 (+0.15%)
  • OIL

    +0.67 (+0.77%)
  • GOLD

    +3.40 (+0.19%)

    -31.99 (-0.23%)
  • FTSE

    +26.91 (+0.36%)
  • Dow Jones

    +239.61 (+0.71%)
  • DAX

    +93.52 (+0.68%)
  • Hang Seng

    +167.27 (+0.84%)
  • NIKKEI 225

    +287.20 (+0.99%)

    +0.1790 (+0.21%)

Is It Time To Consider Buying Bio-Techne Corporation (NASDAQ:TECH)?

·3-min read

Let's talk about the popular Bio-Techne Corporation (NASDAQ:TECH). The company's shares saw significant share price movement during recent months on the NASDAQGS, rising to highs of US$539 and falling to the lows of US$456. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether Bio-Techne's current trading price of US$456 reflective of the actual value of the large-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at Bio-Techne’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change.

View our latest analysis for Bio-Techne

Is Bio-Techne still cheap?

According to my valuation model, Bio-Techne seems to be fairly priced at around 10.64% above my intrinsic value, which means if you buy Bio-Techne today, you’d be paying a relatively reasonable price for it. And if you believe that the stock is really worth $412.29, there’s only an insignificant downside when the price falls to its real value. Although, there may be an opportunity to buy in the future. This is because Bio-Techne’s beta (a measure of share price volatility) is high, meaning its price movements will be exaggerated relative to the rest of the market. If the market is bearish, the company’s shares will likely fall by more than the rest of the market, providing a prime buying opportunity.

What does the future of Bio-Techne look like?


Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. Bio-Techne's earnings over the next few years are expected to double, indicating a very optimistic future ahead. This should lead to stronger cash flows, feeding into a higher share value.

What this means for you:

Are you a shareholder? It seems like the market has already priced in TECH’s positive outlook, with shares trading around its fair value. However, there are also other important factors which we haven’t considered today, such as the track record of its management team. Have these factors changed since the last time you looked at the stock? Will you have enough conviction to buy should the price fluctuates below the true value?

Are you a potential investor? If you’ve been keeping tabs on TECH, now may not be the most advantageous time to buy, given it is trading around its fair value. However, the optimistic prospect is encouraging for the company, which means it’s worth further examining other factors such as the strength of its balance sheet, in order to take advantage of the next price drop.

If you'd like to know more about Bio-Techne as a business, it's important to be aware of any risks it's facing. For example - Bio-Techne has 2 warning signs we think you should be aware of.

If you are no longer interested in Bio-Techne, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at)

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting